Aptevo Therapeutics Inc. Financing Cash Flow
Aptevo Therapeutics Inc. (APVO) reported Financing Cash Flow of $1.60 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $726.00K, a 94.95% decline year-over-year.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $871.00K.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $5.79M, a 13.78% decline year-over-year.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $18.34M, a 273.58% increase year-over-year.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2025 was $38.50M, a 146.85% increase from fiscal 2024.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2024 was $15.60M, a 160.00% increase from fiscal 2023.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2023 was $6.00M.
- Aptevo Therapeutics Inc. net cash provided by (used in) financing activities for fiscal 2022 was -$2.62M, a 110.00% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $726.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.60M 10-Q · filed 2026-08-14 | $7.39M derived: sum of 3 quarters · filed 2026-08-14 | $25.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $871.00K 10-Q · filed 2026-05-13 | $6.67M derived: sum of 2 quarters · filed 2026-05-13 | $25.00M derived: sum of 3 quarters · filed 2026-05-13 | $39.37M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $24.13M derived: sum of 2 quarters · filed 2026-03-26 | $38.50M derived: sum of 3 quarters · filed 2026-08-14 | $38.50M 10-K · filed 2026-03-26 |
| 2025-09-30 | $18.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $32.70M derived: sum of 2 quarters · filed 2026-08-14 | $32.70M 10-Q · filed 2025-11-06 | $39.42M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $14.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $14.36M 10-Q · filed 2026-08-14 | $21.08M derived: sum of 3 quarters · filed 2026-08-14 | $25.99M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $6.72M derived: sum of 2 quarters · filed 2026-05-13 | $11.63M derived: sum of 3 quarters · filed 2026-05-13 | $15.60M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $6.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $11.63M derived: sum of 2 quarters · filed 2026-03-26 | $15.60M derived: sum of 3 quarters · filed 2026-03-26 | $15.60M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.88M derived: sum of 2 quarters · filed 2025-11-06 | $8.88M 10-Q · filed 2025-11-06 | $11.92M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $3.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $3.97M 10-Q · filed 2025-08-11 | $7.01M derived: sum of 3 quarters · filed 2025-08-11 | $11.36M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$3.00K 10-Q · filed 2025-05-15 | $3.04M derived: sum of 2 quarters · filed 2025-05-15 | $7.39M derived: sum of 3 quarters · filed 2025-05-15 | $7.87M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $7.39M derived: sum of 2 quarters · filed 2025-02-14 | $7.87M derived: sum of 3 quarters · filed 2025-02-14 | $6.00M 10-K · filed 2025-02-14 |
| 2023-09-30 | $4.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.83M derived: sum of 2 quarters · filed 2024-11-07 | $2.95M 10-Q · filed 2024-11-07 | $8.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $481.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.39M 10-Q · filed 2024-08-08 | $4.61M derived: sum of 3 quarters · filed 2024-08-08 | $4.11M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.87M 10-Q · filed 2024-05-08 | $4.13M derived: sum of 2 quarters · filed 2024-05-08 | $3.63M derived: sum of 3 quarters · filed 2024-05-08 | $447.00K derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $5.50M derived: sum of 2 quarters · filed 2024-03-05 | $2.32M derived: sum of 3 quarters · filed 2024-03-05 | -$2.62M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$3.68M derived: sum of 2 quarters · filed 2023-11-14 | -$8.61M 10-Q · filed 2023-11-14 | -$11.69M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$8.11M 10-Q · filed 2023-08-10 | -$11.19M derived: sum of 3 quarters · filed 2023-08-10 | -$14.21M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$4.94M 10-Q · filed 2023-05-11 | -$8.01M derived: sum of 2 quarters · filed 2023-05-11 | -$11.03M derived: sum of 3 quarters · filed 2023-05-11 | -$2.72M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$6.10M derived: sum of 2 quarters · filed 2023-03-30 | $2.22M derived: sum of 3 quarters · filed 2023-03-30 | $26.16M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $5.29M derived: sum of 2 quarters · filed 2022-11-10 | $29.24M 10-Q · filed 2022-11-10 | $50.48M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $8.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $32.26M 10-Q · filed 2022-08-11 | $53.51M derived: sum of 3 quarters · filed 2022-08-11 | $78.24M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $23.94M 10-Q · filed 2022-05-12 | $45.19M derived: sum of 2 quarters · filed 2022-05-12 | $69.92M derived: sum of 3 quarters · filed 2022-05-12 | $69.92M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $21.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $45.98M derived: sum of 2 quarters · filed 2022-03-24 | $45.98M derived: sum of 3 quarters · filed 2022-03-24 | $23.87M 10-K · filed 2022-03-24 |
| 2020-09-30 | $24.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $24.73M derived: sum of 2 quarters · filed 2021-11-12 | $2.63M 10-Q · filed 2021-11-12 | $2.49M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$22.10M 10-Q · filed 2021-08-12 | -$22.24M derived: sum of 3 quarters · filed 2021-08-12 | -$22.21M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$22.10M 10-Q · filed 2021-05-11 | -$22.24M derived: sum of 2 quarters · filed 2021-05-11 | -$22.21M derived: sum of 3 quarters · filed 2021-05-11 | -$22.33M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$111.00K derived: sum of 2 quarters · filed 2021-03-31 | -$224.00K derived: sum of 3 quarters · filed 2021-03-31 | $20.15M 10-K · filed 2021-03-31 |
| 2019-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$89.00K derived: sum of 2 quarters · filed 2020-11-10 | $20.28M 10-Q · filed 2020-11-10 | $20.32M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $20.26M 10-Q · filed 2020-08-14 | $20.30M derived: sum of 3 quarters · filed 2020-08-14 | $19.72M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $20.37M 10-Q · filed 2020-05-13 | $20.41M derived: sum of 2 quarters · filed 2020-05-13 | $19.83M derived: sum of 3 quarters · filed 2020-05-13 | $20.14M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | $39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$544.00K derived: sum of 2 quarters · filed 2020-03-25 | -$231.00K derived: sum of 3 quarters · filed 2020-03-25 | -$787.00K 10-K · filed 2020-03-25 |
| 2018-09-30 | -$583.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$270.00K derived: sum of 2 quarters · filed 2019-11-07 | -$826.00K 10-Q · filed 2019-11-07 | -$299.00K derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | $313.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$243.00K 10-Q · filed 2019-08-09 | $284.00K derived: sum of 3 quarters · filed 2019-08-09 | $102.00K derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$556.00K 10-Q · filed 2019-05-09 | -$29.00K derived: sum of 2 quarters · filed 2019-05-09 | -$211.00K derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $345.00K derived: sum of 2 quarters · filed 2019-03-18 | $19.53M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$182.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $19.01M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $19.19M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |